First, the assessment of CSF YKL-40 concentration at a single time point limited our ability to ascertain the impact of changes in YKL-40 levels on the primary AD-related pathologies, highlighting a significant area for future research endeavors. The gene discussed is CHI3L1; the disease is Alzheimer disease.